CWA Asset Management Group LLC Boosts Stake in Cencora, Inc. (NYSE:COR)

CWA Asset Management Group LLC grew its stake in Cencora, Inc. (NYSE:COR) by 23.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,562 shares of the company’s stock after purchasing an additional 298 shares during the quarter. CWA Asset Management Group LLC’s holdings in Cencora were worth $351,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Concord Wealth Partners acquired a new stake in Cencora during the third quarter valued at approximately $30,000. SYSTM Wealth Solutions LLC bought a new stake in shares of Cencora in the 2nd quarter valued at approximately $36,000. Ashton Thomas Securities LLC bought a new stake in shares of Cencora in the 3rd quarter valued at approximately $41,000. Fairscale Capital LLC acquired a new stake in shares of Cencora during the 2nd quarter valued at approximately $54,000. Finally, Modus Advisors LLC bought a new position in Cencora during the fourth quarter worth $54,000. Institutional investors own 97.52% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on COR. Leerink Partners dropped their target price on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a report on Monday, October 7th. Mizuho began coverage on shares of Cencora in a research note on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price objective on the stock. Barclays raised their target price on shares of Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Bank of America reaffirmed a “neutral” rating and set a $245.00 target price (down from $275.00) on shares of Cencora in a report on Wednesday, September 18th. Finally, Evercore ISI raised their price target on Cencora from $250.00 to $285.00 and gave the stock an “outperform” rating in a report on Thursday, November 7th. Two analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $275.60.

Cencora Trading Up 1.4 %

NYSE:COR opened at $237.63 on Thursday. The stock has a market cap of $45.93 billion, a price-to-earnings ratio of 31.64, a PEG ratio of 1.54 and a beta of 0.49. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88. Cencora, Inc. has a 1 year low of $209.32 and a 1 year high of $253.27. The business has a fifty day moving average of $237.38 and a 200-day moving average of $233.51.

Cencora Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, November 29th. Investors of record on Friday, November 15th were given a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.93%. The ex-dividend date of this dividend was Friday, November 15th. This is a positive change from Cencora’s previous quarterly dividend of $0.51. Cencora’s dividend payout ratio is currently 29.29%.

Insider Buying and Selling at Cencora

In other Cencora news, Chairman Steven H. Collis sold 50,000 shares of the stock in a transaction on Monday, November 25th. The stock was sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the completion of the transaction, the chairman now directly owns 326,557 shares of the company’s stock, valued at approximately $79,670,111.29. This trade represents a 13.28 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Silvana Battaglia sold 1,678 shares of the business’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the completion of the sale, the executive vice president now directly owns 20,329 shares in the company, valued at $4,649,648.88. This represents a 7.62 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 94,696 shares of company stock valued at $22,862,734. Company insiders own 15.80% of the company’s stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.